SCHEMBL22436747

SCHEMBL22436747

C=CC(=O)c1cc(CC)n(C)n1

nearest known ligand 0.37

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
THRB P10828 6/20 0.37
BAZ2B Q9UIF8 1/20 0.33
THRA P10827 5/20 0.32
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
MPO P05164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6079670 0.79 BAZ2B (0.37) BAZ2BMEN1KMT2AMPO
SCHEMBL3576265 0.79 HCAR2 (0.42) BAZ2B
SCHEMBL1233408 0.77 PLA2G10 (0.45) BAZ2BMPO
SCHEMBL9197577 0.75 MMP2 (0.43) BAZ2BMEN1KMT2AMPO
SCHEMBL19635568 0.75 BAZ2B (0.34) BAZ2BMPO
SCHEMBL1233249 0.73 MPO (0.49) MEN1KMT2AMPO
SCHEMBL19635566 0.71 MPO (0.40) BAZ2BMEN1KMT2AMPO
SCHEMBL14642681 0.70
SCHEMBL11455736 0.70 KDM4E (0.34) BAZ2BMEN1KMT2A
SCHEMBL13466375 0.70 KDM4C (0.48) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11891404-B2 Substituted macrocyclic indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2024-02-06 US disclosed
CN-111757884-B Substituted macrocyclic indole derivatives 拜耳股份公司 2023-12-19 CN disclosed
US-20230112244-A1 SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
US-11440923-B2 Substituted macrocyclic indole derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-09-13 US disclosed
US-11440923-B2 Substituted macrocyclic indole derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-09-13 US disclosed
CN-111757884-A Substituted macrocyclic indole derivatives 拜耳股份公司 2020-10-09 CN disclosed
EP-3710451-A1 SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES Bayer Aktiengesellschaft (DE) 2020-09-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230112244-A1 SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES FOXM1, CCND2, CCNI THRB 922/4885BAZ2B 1257/4885THRA 618/4885
US-11891404-B2 Substituted macrocyclic indole derivatives FOXM1, CCND2, CCNI THRB 922/4885BAZ2B 1257/4885THRA 618/4885
US-11440923-B2 Substituted macrocyclic indole derivatives FOXM1, CCND2, CCNI THRB 922/4885BAZ2B 1257/4885THRA 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.